Vertex’s Orkambi receives EC approval
Orkambi is an oral treatment for very young children that combines both lumacaftor and ivacaftor
Read More
Tag: orkambi
Vertex signs ‘landmark’ deal with NHS for CF therapy
CF patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the EC
Read More
Scotland and Vertex strike CF drug deal
Back in August, the SMC rejected Orkambi and Symkevi following consideration through PACE.
Read More
Orkambi’s use expanded for younger children
The European Commission has expanded the use of Orkambi to include children with cystic fibrosis aged two years to five years.
Read More
Vertex to submit Orkambi, Symkevi to SMC
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Read More
MPs order release of documents on negotiations for Vertex’ CF drugs
The UK House of Commons’ Health and Social Care Committee has requested documents and evidence from Vertex Pharmaceuticals, NHS England and the National Institute for Health and Care Excellence (NICE) regarding ongoing and lengthy negotiations about NHS funding for the firm’s cystic fibrosis treatments.
Read More
Vertex mulls over NHS England’s offer for CF drugs
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Read More
Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.
Read More
Ministers write letter to Vertex over Orkambi debate
Ministers from the Department of Health have written a letter asking that Vertex bring negotiations with NHS England over access to cystic fibrosis drug Orkambi “to an urgent resolution”.
Read More
MPs call on government to help with Orkambi debate
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
Read More
Vertex offers ‘portfolio approach’ to secure access to CF meds
Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis (CF) medicines.
Read More
Vertex’ CF therapy Orkambi cleared for younger patients
European regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
